Noteworthily, CRC involves immune evasion pathways beyond PD-1/PD-L1 and CTLA4, with emerging targets like LAG3, TIM-3, and TIGIT under clinical investigations (65, 66). This evidence concerns the gene LAG3 and colorectal carcinoma.